IgM Neutralizing Antibody Responses to Human Herpesvirus-6 in Patients with Exanthem Subitum or Organ Transplantation
-
- SUGA Sadao
- Department of Pediatrics, Fujita Health University School of Medicine
-
- YOSHIKAWA Tetsushi
- Department of Pediatrics, Fujita Health University School of Medicine
-
- ASANO Yoshizo
- Department of Pediatrics, Fujita Health University School of Medicine
-
- NAKASHIMA Toshihiko
- Department of Pediatrics, Fujita Health University School of Medicine
-
- YAZAKI Takehiko
- Department of Pediatrics, Fujita Health University School of Medicine
-
- FUKUDA Minoru
- Division of Hematology-Oncology, Children's Medical Center, the Japanese Red Cross Nagoya First Hospital
-
- KOJIMA Seiji
- Division of Hematology-Oncology, Children's Medical Center, the Japanese Red Cross Nagoya First Hospital
-
- MATSUYAMA Takaharu
- Division of Hematology-Oncology, Children's Medical Center, the Japanese Red Cross Nagoya First Hospital
-
- ONO Yoshinari
- Department of Urology, Komaki Shimin Hospital
-
- OSHIMA Shinichi
- Department of Urology, Chukyo Hospital
抄録
The assay for detecting IgM neutralizing (NT) antibody activity to human herpesvirus-6 (HHV-6) was developed by using pretreatment of blood sample with staphylococcal protein A. The activity was mostly present in IgM fractions of serum but not in IgA fractions separated by ultracentrifugation. The assay was used for seroepidemiological studies for HHV-6 infection. In primary HHV-6 infection, IgM NT antibodies appeared 5 to 7 days after onset of exanthem subitum, reached maximum titers at 2 to 3 weeks, and tended to decline to undetectable levels after 2 months. In contrast, reactivation of HHV-6 observed in organ transplants showed somewhat greater degree of IgM NT antibody responses that persisted for 2 to 3 months and became undetectable 5 to 6 months after transplantation. The level and persistence of NT antibody titers measured by the conventional method was generally greater than those of the IgM titers. The prevalence of the IgM NT antibodies was examined in healthy individuals. The antibody was first detected at 4 to 7 months of age (5%), reached maximum level at 8 to 11 months (40%), and was detectable by 4 to 6 years (17%). A few (4 to 5%) of adolescents and adults were positive for the antibody.
収録刊行物
-
- MICROBIOLOGY and IMMUNOLOGY
-
MICROBIOLOGY and IMMUNOLOGY 36 (5), 495-506, 1992
Center For Academic Publications Japan
- Tweet
詳細情報
-
- CRID
- 1573950402848052224
-
- NII論文ID
- 130003483881
-
- ISSN
- 03855600
-
- 本文言語コード
- en
-
- データソース種別
-
- CiNii Articles